EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29453701.
- Also identified by DOI 10.1007/s00259-018-3947-x and PMC identifier 5978928.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (<sup>89</sup>Sr), samarium-153 (<sup>153</sup>Sm) lexidronam (<sup>153</sup>Sm-EDTMP), and phosphorus-32 (<sup>32</sup>P) sodium phosphate; (b) performing the treatments; and
Medical subject headings
- Bone Neoplasms
- Prostatic Neoplasms
- Radioisotopes